四环医药完成利拉鲁肽 I 期研究,即将开展肥胖 III 期研究

2021-03-07 医药魔方 医药魔方

2月26日,四环医药发布公告,称集团的利拉鲁肽项目已完成治疗2型糖尿病和肥胖的I期临床研究。并初步获得了药代动力学和药效学的生物等效性结果。并表示目前正在进行肥胖症III期开发计划沟通中,不久将进入I

2月26日,四环医药发布公告,称集团的利拉鲁肽项目已完成治疗2型糖尿病和肥胖的I期临床研究。并初步获得了药代动力学和药效学的生物等效性结果。并表示目前正在进行肥胖症III期开发计划沟通中,不久将进入III期临床阶段。

利拉鲁肽(liraglutide)是一种血糖高血糖素样肽-1(GLP-1)激动剂,被FDA批准用于治疗成人及十岁以上2型糖尿病患者,且用于降低 2型糖尿病患者高血压,卒中血管死亡风险。此外,临床试验中,利拉鲁肽还显示出改善肥胖相关合并症的潜力。

在中国,诺和诺德开发的的Victoza(利拉鲁肽)于2017年进入国家医保目录之后明显放量,2019年收入达到人民币9.26亿元,同比增长70%。

根据诺和诺德财报披露,其利拉鲁肽减肥产品Saxenda在2020年全球实现了8.58亿美元的收益,该产品是拉动诺和诺德全球业绩增长的主要因素。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1916411, encodeId=0d96191641160, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Feb 01 11:18:04 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976984, encodeId=d81a9e698481, content=<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>仿制药出得快, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Sat Jun 26 08:33:52 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961674, encodeId=93429616e420, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210429/ae7abaf6ff97425d8359abc0015dc0c8/4d55796c5cd848f4a5756ded5d0c941a.jpg, createdBy=dc4e5447137, createdName=ms4000001291496338, createdTime=Thu Apr 29 22:43:14 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410109, encodeId=6657141010906, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Tue Mar 09 05:18:04 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946236, encodeId=e8fc9462363d, content=好好看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a735466553, createdName=ms9000000603431297, createdTime=Sun Mar 07 20:12:11 CST 2021, time=2021-03-07, status=1, ipAttribution=)]
    2022-02-01 juliusluan78
  2. [GetPortalCommentsPageByObjectIdResponse(id=1916411, encodeId=0d96191641160, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Feb 01 11:18:04 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976984, encodeId=d81a9e698481, content=<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>仿制药出得快, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Sat Jun 26 08:33:52 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961674, encodeId=93429616e420, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210429/ae7abaf6ff97425d8359abc0015dc0c8/4d55796c5cd848f4a5756ded5d0c941a.jpg, createdBy=dc4e5447137, createdName=ms4000001291496338, createdTime=Thu Apr 29 22:43:14 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410109, encodeId=6657141010906, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Tue Mar 09 05:18:04 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946236, encodeId=e8fc9462363d, content=好好看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a735466553, createdName=ms9000000603431297, createdTime=Sun Mar 07 20:12:11 CST 2021, time=2021-03-07, status=1, ipAttribution=)]
    2021-06-26 小小医者

    #利拉鲁肽#仿制药出得快

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1916411, encodeId=0d96191641160, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Feb 01 11:18:04 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976984, encodeId=d81a9e698481, content=<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>仿制药出得快, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Sat Jun 26 08:33:52 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961674, encodeId=93429616e420, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210429/ae7abaf6ff97425d8359abc0015dc0c8/4d55796c5cd848f4a5756ded5d0c941a.jpg, createdBy=dc4e5447137, createdName=ms4000001291496338, createdTime=Thu Apr 29 22:43:14 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410109, encodeId=6657141010906, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Tue Mar 09 05:18:04 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946236, encodeId=e8fc9462363d, content=好好看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a735466553, createdName=ms9000000603431297, createdTime=Sun Mar 07 20:12:11 CST 2021, time=2021-03-07, status=1, ipAttribution=)]
    2021-04-29 ms4000001291496338

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1916411, encodeId=0d96191641160, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Feb 01 11:18:04 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976984, encodeId=d81a9e698481, content=<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>仿制药出得快, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Sat Jun 26 08:33:52 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961674, encodeId=93429616e420, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210429/ae7abaf6ff97425d8359abc0015dc0c8/4d55796c5cd848f4a5756ded5d0c941a.jpg, createdBy=dc4e5447137, createdName=ms4000001291496338, createdTime=Thu Apr 29 22:43:14 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410109, encodeId=6657141010906, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Tue Mar 09 05:18:04 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946236, encodeId=e8fc9462363d, content=好好看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a735466553, createdName=ms9000000603431297, createdTime=Sun Mar 07 20:12:11 CST 2021, time=2021-03-07, status=1, ipAttribution=)]
    2021-03-09 cathymary
  5. [GetPortalCommentsPageByObjectIdResponse(id=1916411, encodeId=0d96191641160, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Feb 01 11:18:04 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976984, encodeId=d81a9e698481, content=<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>仿制药出得快, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Sat Jun 26 08:33:52 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961674, encodeId=93429616e420, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210429/ae7abaf6ff97425d8359abc0015dc0c8/4d55796c5cd848f4a5756ded5d0c941a.jpg, createdBy=dc4e5447137, createdName=ms4000001291496338, createdTime=Thu Apr 29 22:43:14 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410109, encodeId=6657141010906, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Tue Mar 09 05:18:04 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946236, encodeId=e8fc9462363d, content=好好看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a735466553, createdName=ms9000000603431297, createdTime=Sun Mar 07 20:12:11 CST 2021, time=2021-03-07, status=1, ipAttribution=)]
    2021-03-07 ms9000000603431297

    好好看看

    0

相关资讯

诺和诺德的长效化凝血因子VIII(ESPEROCT)获FDA批准治疗A型血友病

ESPEROCT是长效化的先天性凝血因子VIII,目前被批准用于成人和儿童A型血友病(先天性凝血因子VIII缺乏)的常规预防使用,以减少出血发作的频率。同时也被批准用于按需治疗围手术期的出血事件。

Ozempic被批准用于患有心脏病的2型糖尿病患者

FDA已经批准了诺和诺德(Novo Nordisk)糖尿病药物,即每周一次的GLP-1激动剂Ozempic(semaglutide)的适应症扩展,新标签用于降低患有心脏病的2型糖尿病患者发生重大不良心血管事件(MACE)的风险。

欧洲药品管理局的CHMP支持诺和诺德口服GLP-1受体激动剂Rybelsus,用于治疗2型糖尿病

诺和诺德(Novo Nordisk)宣布,欧洲药品管理局的人用药品管理委员会(CHMP)采纳了一项积极意见,建议批准其口服GLP-1受体激动剂Rybelsus(semaglutide)用于治疗2型糖尿病控制不佳的成年人,作为饮食和运动的辅助手段来改善血糖控制。监管机构指出,该药物是开发用于口服的首个GLP-1受体激动剂治疗药物。

Oxford Biomedica获得诺和诺德5300万英镑现金投资,开发细胞和基因疗法

细胞和基因治疗公司Oxford Biomedica从Novo Holdings获得了5350万英镑的现金投资,以换取该公司10%的股份。

来了!诺和诺德正式提交「口服索马鲁肽」上市申请,并动用优先审评券

3月20日,诺和诺德宣布向FDA提交了口服索马鲁肽的两项新药上市申请(NDA)。其中一项是寻求FDA批准口服索马鲁肽辅助饮食和运动用于改善2型糖尿病患者的血糖控制。诺和诺德为此项申请还使用了优先审评券,使得该申请的审批周期缩短至6个月。另外一项则是寻求FDA批准口服索马鲁肽用于降低确定伴有心血管疾病的成人2型糖尿病患者的主要心血管事件(包括心脏病发作、卒中和死亡)风险。该申请走标准审评程序,审批周

肥胖症治疗:诺和诺德的AM833在两项临床试验成功减轻患者体重

“AM833有潜力缩小药物治疗和减肥手术之间的差距”